Less than 1 min.Read

Immutep: Reveals encouraging interim results from phase two TACTI-002 study

November 10, 2020

Immutep (IMM) has released further interim data from its Phase II TACTI-002 Study in patients with lung, head, and neck cancers
The study evaluates a combined treatment using Immutep’s eftilagimod alpha (efti) with MSD’s KEYTRUDA (also known as pembrolizumab) candidate
Efti is a soluble LAG-3 fusion protein and antigen-presenting cell activator, while pembrolizumab is a PD-1 inhibitor
So far, results show the combined treatment has therapeutic benefits and a good safety profile, standing it in good stead for further clinical development
Immutep will enrol up to 25 extra patients in the study and expects to report more mature trial data in the first half of 2021
Shares have been trading 1.7 per cent lower at 29 cents